Tiziana Life Sciences (NASDAQ:TLSA) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Tiziana Life Sciences (NASDAQ:TLSA) from a strong sell rating to a sell rating in a research report report published on Saturday morning,Wall Street Zen reports.

A number of other equities analysts also recently commented on TLSA. Weiss Ratings upgraded Tiziana Life Sciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, October 19th. BTIG Research restated a “buy” rating on shares of Tiziana Life Sciences in a report on Tuesday, September 22nd. Finally, Zacks Research upgraded Tiziana Life Sciences to a “hold” rating in a report on Tuesday, July 14th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold”.

Tiziana Life Sciences Stock Performance

TLSA stock opened at $0.88 on Friday. The business has a 50 day simple moving average of $1.02 and a 200-day simple moving average of $1.23. Tiziana Life Sciences has a 1 year low of $0.76 and a 1 year high of $2.10.

Insider Buying and Selling

In other news, CEO Ivor Elrifi bought 667,000 shares of Tiziana Life Sciences stock in a transaction on Monday, August 3rd. The shares were bought at an average cost of $1.00 per share, with a total value of $667,000.00. Following the completion of the purchase, the chief executive officer directly owned 4,472,261 shares of the company’s stock, valued at approximately $4,472,261. This trade represents a 17.53% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have bought 988,423 shares of company stock worth $985,909 over the last quarter. 39.82% of the stock is owned by insiders.

Institutional Trading of Tiziana Life Sciences

An institutional investor recently bought a new stake in Tiziana Life Sciences stock. Mid American Wealth Advisory Group Inc. purchased a new position in shares of Tiziana Life Sciences Ltd (NASDAQ:TLSA) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 323,240 shares of the company’s stock, valued at approximately $414,000. Mid American Wealth Advisory Group Inc. owned about 0.25% of Tiziana Life Sciences at the end of the most recent reporting period.

Tiziana Life Sciences Company Profile

Tiziana Life Sciences Ltd. (NASDAQ: TLSA) is a clinical-stage biotechnology company developing therapies that modulate the immune system to treat neuroinflammatory and neurodegenerative diseases. The company’s lead product candidate is foralumab, a fully human monoclonal antibody designed to target the CD3 receptor on T cells and potentially reduce harmful immune activation.

Tiziana is primarily evaluating an intranasal formulation of foralumab in conditions involving inflammation of the central nervous system, including non-active secondary progressive multiple sclerosis and Alzheimer’s disease.